Thor Halfdanarson: The trial us CUP folks have been waiting for, CUPISCO
Thor Halfdanarson, North American Neuroendocrine Tumor Society, shared a post on X
“The trial us CUP folks have been waiting for, CUPISCO
PFS better with molecularly-guided treatment but the difference is modest, 6.1 vs. 4.4 mos but better in the subgroup with actionable alterations.
Importantly, complex trials in rare cancers can be done, bravo”
Authors: Alwin Krämer, Tilmann Bochtler, Chantal Pauli, Kai-Keen Shiu, Natalie Cook, Juliana Janoski de Menezes, Roberto A Pazo-Cid, Ferran Losa, Debbie Gj Robbrecht, Jiří Tomášek , Cagatay Arslan, Mustafa Özgüroğlu, Michael Stahl, Frédéric Bigot, Sun Young Kim, Yoichi Naito, Antoine Italiano, Nasséra Chalabi, Gonzalo Durán-Pacheco, Chantal Michaud, Jeremy Scarato, Marlene Thomas, Jeffrey S Ross , Holger Moch, and Linda Mileshkin .
Source: Thor Halfdanarson/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023